Edmic Bio (CEO Ha Dong-heon) is a company that develops a “long-term chip platform” used to develop new drugs and prescribe patient-specific drugs with 3D bioprinting technology.
Admic Bio is a company that develops long-term chips based on 3D bio-printing, bio-ink, and micro-current technology. The photo shows Ha Dong-hun, CEO of Edmic Bio. Edmic Bio is provided
Admic Bio is a company that develops long-term chips based on 3D bio-printing, bio-ink, and micro-current technology. The photo shows Ha Dong-hun, CEO of Edmic Bio. Edmic Bio is provided
Organ chips are platforms that implement organs in the body outside the body and conduct various experiments. In order to develop new drugs, non-clinical trials such as cells and animals are conducted, but non-clinical trials are different from the actual human environment, so there is a problem that the accuracy falls below 8%.
Organ chips are implemented similarly to actual organs, and three factors are essential to increase accuracy: “long-term physical environment,” “long-term biochemical environment,” and “long-term flow environment.”
Edmic Bio is a company with all the essential elements ▲ More than 15 years of 3D bioprinting research experience ▲ The world’s first organization and long-term bio-ink capable of 3D printing and has technology to create an environment close to the actual long-term.
Edmic Bio implements long-term chips based on 3D bio-printing ▲ bio-ink extracted directly from tissues and organs that simulate the physical environment of ▲ organs and micro-fluidic technologies that help efficient experiments with the flow environment.
Through this, animal testing can be replaced in the process of developing new drugs, and several anticancer drugs can be tested with cancer chips using patients’ cancer cells, and the results can be provided to patients to expect better prognosis.
Edmic Bio aims to implement a “patient-tailored drug prescription platform.” After cancer cells in cancer patients are made into organ chips, effective combinations of various drugs are found to enable more accurate prescription and treatment.
Edmic Bio has also secured a technological foundation comparable to a global organ chip company by receiving DNA transplants from Pohang University of Science and Technology.